Activated T cells and cytokine-induced CD3+CD56+ killer cells

被引：0

作者：

G. D. Schmidt-Wolf

R. S. Negrin

I. G. H. Schmidt-Wolf

机构：

[1] Department of Medicine,

[2] Division of Hematology/Oncology,undefined

[3] Virchow Clinic of Humboldt University,undefined

[4] Augustenburger Platz 1,undefined

[5] D-13353 Berlin,undefined

[6] Germany,undefined

[7] Bone Marrow Transplantation Program,undefined

[8] Stanford University Medical Center,undefined

[9] Stanford,undefined

[10] CA,undefined

[11] USA,undefined

来源：

Annals of Hematology | 1997年 / 74卷

关键词：

Key words T cells; Cytokine-induced killer cells; Immunotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells may be suitable to remove residual tumor cells.

引用

页码：51 / 56

页数：5